INOVIO Pharmaceuticals, Inc.
Drugmaker with rare disease work · based in Plymouth Meeting, United States · ticker INO · inovio.com
INOVIO Pharmaceuticals, Inc. works on Recurrent Respiratory Papillomatosis, one of the rare diseases we track.
INOVIO is a biotechnology company in Plymouth Meeting, Pennsylvania, that develops DNA medicines for HPV-related diseases, cancer and infectious diseases. Its lead candidate, INO-3107, is under FDA review for recurrent respiratory papillomatosis, with a decision due October 30, 2026, and holds Orphan Drug and Breakthrough Therapy designations.
INOVIO Pharmaceuticals, Inc. clinical trials
We did not find active INOVIO Pharmaceuticals, Inc. trials for the rare diseases we track on ClinicalTrials.gov right now.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only INOVIO Pharmaceuticals, Inc.. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Recurrent Respiratory Papillomatosis. Turn any of these off from the link in every email.
More about INOVIO Pharmaceuticals, Inc.
Within its broader pharmaceutical portfolio, INOVIO Pharmaceuticals, Inc. has active clinical trial programs and drug development efforts across 1 rare diseases, including Recurrent Respiratory Papillomatosis. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by INOVIO Pharmaceuticals, Inc., sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
INOVIO Pharmaceuticals, Inc. is headquartered in Plymouth Meeting, United States, publicly traded under the ticker symbol INO. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Rare diseases INOVIO Pharmaceuticals, Inc. works on
Each disease page lists every open trial, not only INOVIO Pharmaceuticals, Inc.'s, plus approved treatments.
Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis (RRP) is a rare disease in which wart-like growths caused by HPV types 6 and 11 grow in the airway, most often on the voice box.
How common: In the US, CDC estimates put new cases at 2 or fewer per 100,000 children and 2 to 3 per 100,000 adults (NIDCD), and the FDA counts about 1,000 new cases a year
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. INOVIO Pharmaceuticals, Inc.'s own site is inovio.com, and our help paying for treatment page lists drugmaker programs and charity funds.
- NIDCD - Recurrent Respiratory PapillomatosisRecurrent Respiratory Papillomatosis
- FDA - FDA Approves First Immunotherapy for Recurrent Respiratory PapillomatosisRecurrent Respiratory Papillomatosis